FDA's enforcement actions against biotech firms increase by 25% in 6 months

The leadership turmoil will cause the FDA to overcompensate by ramping up inspections and warning letters to biotech and pharmaceutical firms to demonstrate continuity. This follows a period of relatively lenient enforcement in early 2026.

Implied probability (Yes)

68%